N/A N=6 Effects of Estrogen Deficiency on Energy Expenditure
Obesity
Primary: Brown Adipose Tissue Activity — 3.9; 4.0 Standard uptake value (SUV) — p=0.84
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Bone Mineral Density (BMD) of Lumbar Spine by Dual Energy X-ray Absorptiometry (DXA) — 2.0 percent change
Phase 2 N=35 Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women
Cardiovascular Risk Reduction
Primary: Arterial Stiffness — 10.1; 14.8; 6.4; 12.7 mm Hg
Phase 3 N=79 Prevention of Obesity in Women Via Estradiol Regulation
Obesity
Primary: Resting Energy Expenditure (REE) — -37.8; -87.2; 14.6; -19.3 kcal/d — p=<0.05
Phase 4 N=34 Estrogen Variability and Irritability During the Menopause Transition
Menopause · Irritable Mood
Primary: Mean IDAS Ill Temper Scale Score Over Time — 6.19; 6.02 score on a scale — p=0.09
N/A N=17 Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
Cognitive Impairment · Executive Dysfunction · Endothelial Dysfunction
Primary: Changes in Prefrontal Cortex Brain Activation at 6 Months — 90.64; -62.20; 28.07; -79.04 beta-weight
Phase 3 N=172 Perimenopausal Estrogen Replacement Therapy Study
Perimenopause · Menopause · Depression
Primary: Change in Depressive Symptoms as Indicated by The Center for Epidemiologic Studies Depression Scale (CES-D) — 1.04; -1.02 units on a scale
Phase 2 N=14 Estradiol Levels in Patients Treated With Estring
Estrogen Levels Among Breast Cancer Patients
Primary: Changes in Serum Estradiol — 3.9 pg/mL
Phase 2 N=38 Aging and Estrogen on Cortical Function
Memory Loss · Cognitive Changes · Postmenopausal Symptoms
Primary: Functional Magnetic Resonance Imaging (fMRI) Changes in Response to Estrogen and Aging - Dorsolateral Pre-frontal Cortex (DLPFC) — 455.8; -214.4; -348.1; 90.1 linear…
Phase 2 N=25 Postmenopausal Women Estrogen and Progesterone Infusion
Postmenopause · Aging
Primary: Effect of Aging on Estrogen Negative Feedback on LH — -52.8; -53.2 % change from baseline — p=0.90
Phase 1 N=30 Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women
Healthy
Primary: Mean Baseline GH Concentration — 0.23; 0.096 ug/L — p=<0.05
Phase 2 N=29 Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women
Estrogen Deficiency · Cardiovascular Disease (CVD) · Functional Hypothalamic Amenorrhea
Primary: Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry — 0.20; 0.25 change of RHI
Phase 4 N=64 Perimenopausal Effects of Estradiol on Reward Responsiveness
Perimenopausal Depression
Primary: Caudate Signal Intensity in Response to Reward During the MID fMRI Task at Pre-treatment — .027; .043 percent signal change — p=.620
N/A N=47 Estrogen and Serotonin on Changing Brain Chemistry
Menopause
Primary: Percent Change in BOLD Signal — -.43; .20 percentage of BOLD signal changes
Phase 3 N=248 Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms
Menopause · Osteoporosis · Osteopenia
Primary: Change From Baseline in Bone Mineral Density — 1.146; 1.132 g/cm2
Phase 2 N=283 Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy
Vaginal Atrophy
Primary: Change From Baseline to Week 12 in the Severity of Vaginal Dryness — 15; 13; 13; 9 Participants — p==0.304
Phase 2 N=46 Estrogen Receptor Beta and Mood
Perimenopause-Related Depression
Primary: Center for Epidemiologic Studies-Depression (CES-D) Scale Mean Total Score — 12.96; 18.02; 11.53; 9.43 Units on a scale
Phase 4 N=60 Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial
HIV Infection · Vaginal Atrophy · Menopause
Primary: Change in Most Bothersome Symptom (MBS) of Vaginal Atrophy — 0; 1; 8; 4 Participants
Phase 3 N=764 Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
Vulvovaginal Atrophy · Menopause · Dyspareunia
Primary: Co-Primary Efficacy Endpoint - Vaginal Superficial Cells — 17.50; 16.72; 23.20; 5.63 percentage of vaginal superficial cells — p=< 0.0001
Phase 4 N=41 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
Turner Syndrome · Hypogonadism · Premature Ovarian Failure
Primary: Change in Weight From Baseline at 12 Months — 1.1; 1.9 kilograms
N/A N=25 Androgen Effects in HIV-infected Women
HIV Infection
Primary: Lean Body Mass — 1.8; 0.8 kilograms — p=0.04
N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
N/A N=31 Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen
Atrophic Vaginitis · Breast Cancer
Primary: Change in Serum Estradiol From Baseline to Week 12 — 5.21; 4.46; 5.23; 6.72 pg/ml
Phase 3 N=20 Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women
Menopause
Primary: Vaginal Cytokines at Baseline — 2.73; 3.19; 0.12; 0.04 pg/ug protein
Phase 3 N=450 Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
Vaginal Atrophy
Primary: Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear — 60.66; 56.74; 59.54; 62.22 percentage of parabasal cells
N/A N=57 Estrogen and Diabetes
Diabetes Mellitus, Type 1
Primary: FMD/Shear — 0.182; 0.206; 0.155; 0.219 %/s^-1
Phase 3 N=1,271 Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
Hypoactive Sexual Desire Disorder
Primary: Incidence of Endometrial Hyperplasia in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Not Using Concomitant Estrogen and Progestin, Year 1…
Phase 3 N=121 Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes
Exercise-related Amenorrhea
Primary: Change in Lumbar Bone Mineral Density — 0.025; 0.008; 0.012 g/cm^2 — p=0.039
N/A N=53 Timing Estrogen After MenoPaUSe
Insulin Resistance
Primary: Insulin-mediated Glucose Disposal Rate (Hyperinsulinemic-euglycemic Clamp) — 11.7; 11.5; 12.2; 10.7 mg/kg FFM/min
Phase 1 N=29 A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women
Postmenopausal Symptoms
Primary: Immunohistochemistry (IHC) Proliferative Effects Measurement — 0.73; 0.43; 0.25 Square root of % positive stained cells — p=<0.001